1. The NHS must act on bevacizumab, for patients' sake.
- Author
-
Fell G
- Subjects
- Angiogenesis Inhibitors pharmacology, Bevacizumab pharmacology, Health Services Accessibility, Humans, Macular Degeneration economics, Receptors, Vascular Endothelial Growth Factor antagonists & inhibitors, United Kingdom epidemiology, Angiogenesis Inhibitors economics, Bevacizumab economics, Cost-Benefit Analysis legislation & jurisprudence, Macular Degeneration drug therapy, Ophthalmologists ethics, Ranibizumab pharmacology, Recombinant Fusion Proteins pharmacology, State Medicine legislation & jurisprudence
- Abstract
Competing Interests: Competing interests: I have undertaken work for Bayer Ophthalmology and Bayer CVD Medicine over four years ago. My employer was reimbursed for my time.
- Published
- 2017
- Full Text
- View/download PDF